Five Prime Therapeutics (FPRX) : The money flow analysis of Five Prime Therapeutics (FPRX) indicates a $2.88 million of outflow was on downticks, whereas, the investors on Tuesday gobbled up stocks worth $4.04 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.4 and so was the total money flow at $1.16 million. The bulls lapped up $0.94 million worth of block trades on upticks. The money flow was $0.94 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Five Prime Therapeutics (FPRX), pushing it down by -1.73% for the day. The stock slid $0.78 and traded at $44.28 during the day. Nonetheless, the stock is -0.58% over the previous weeks close.
The company Insiders own 5.3% of Five Prime Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 15.01% . Institutional Investors own 82.21% of Five Prime Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of 15.01%. In an insider trading activity, Belsky Marc, officer (Senior Vice President and CFO) of Five Prime Therapeutics Inc, unloaded 34,102 shares at an average price of $49.63 on April 22, 2016. The total amount of the transaction was worth $1,692,482, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Shares of Five Prime Therapeutics, Inc. rose by 3.5% in the last five trading days and 3.57% for the last 4 weeks. Five Prime Therapeutics, Inc. has dropped 0.91% during the last 3-month period . Year-to-Date the stock performance stands at 6.99%.
Five Prime Therapeutics (NASDAQ:FPRX): On Tuesdays trading session , Opening price of the stock was $45.2 with an intraday high of $45.9899. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $44.08. However, the stock managed to close at $44.4, a loss of 1.46% for the day. On the previous day, the stock had closed at $45.06. The total traded volume of the day was 501,308 shares.
Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Companys product candidates include FPA008, FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R), that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b), which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. Its partner, GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma.